Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses ...Middle East

Medscape - News
The main composite renal endpoint from VERTIS CV didn't show significant benefit from ertugliflozin over placebo, but in additional analyses showed kidney benefits from this SGLT2 inhibitor. Medscape Medical News

Hence then, the article about ertugliflozin renal benefits in additional vertis cv analyses was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses )

Apple Storegoogle play

Last updated :

Also on site :